Phase II Trial of Temozolomide (TMZ), Motexafin Gadolinium (MGd), and 60 Gy Fractionated Radiation (RT) for Newly Diagnosed Supratentorial Glioblastoma (GBM): Results of RTOG 0513 Conference

Brachman, DG, Wang, M, Ashby, LS et al. (2011). Phase II Trial of Temozolomide (TMZ), Motexafin Gadolinium (MGd), and 60 Gy Fractionated Radiation (RT) for Newly Diagnosed Supratentorial Glioblastoma (GBM): Results of RTOG 0513 . INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(2), S129-S130. 10.1016/j.ijrobp.2011.06.267

Open Access

cited authors

  • Brachman, DG; Wang, M; Ashby, LS; Thomas, TA; Dunbar, EM; Rockhill, JK; Khuntia, D; Bovi, JA; Macher, MS; Mehta, MP

sustainable development goals

authors

publication date

  • January 1, 2011

webpage

published in

keywords

  • Life Sciences & Biomedicine
  • Oncology
  • Radiology, Nuclear Medicine & Medical Imaging
  • Science & Technology

Digital Object Identifier (DOI)

publisher

  • ELSEVIER SCIENCE INC

start page

  • S129

end page

  • S130

volume

  • 81

issue

  • 2